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Abstract
Background: Machupo virus (MACV), a member of the Arenaviridae, causes Bolivian hemorrhagic fever, with ~20%
lethality in humans. The pathogenesis of MACV infection is poorly understood, and there are no clinically proven
treatments for disease. This is due, in part, to a paucity of small animal models for MACV infection in which to
discover and explore candidate therapeutics.
Methods: Mice lacking signal transducer and activator of transcription 1 (STAT-1) were infected with MACV.
Lethality, viral replication, metabolic changes, hematology, histopathology, and systemic cytokine expression were
analyzed throughout the course of infection.
Results: We report here that STAT-1 knockout mice succumbed to MACV infection within 7-8 days, and presented
some relevant clinical and histopathological manifestations of disease. Furthermore, the model was used to
validate the efficacy of ribavirin in protection against infection.
Conclusions: The STAT-1 knockout mouse model can be a useful small animal model for drug testing and
preliminary immunological analysis of lethal MACV infection.
Background
Machupo virus (MACV), a member of the Arenaviridae
family, is the causative agent of Bolivian hemorrhagic
fever. MACV is spread by inhalation of aerosols gener-
ated from excretions of its carrier, the mouse Calomys
callosus, although human-to-human transmission can
also occur [1-3]. Case fatality rates are approximately
20% in humans. The disease course in humans is similar
to other New World arenavirus infections, such as Junín
virus infection, with an incubation period of ~1-2
weeks, followed by fever and malaise, headache, dizzi-
ness, back pain, petechia, erythema, and myalgia
(reviewed in [1]). Leukopenia, thrombocytopenia,
hemorrhaging, and neurological symptoms are often
prominent. Patients that succumb to infection generally
do so 7-12 days after onset of symptoms. Subcutaneous
inoculation of non-human primates (NHPs) results in a
fairly similar disease course to that seen in humans,
with death ranging from 8-25 days after virus exposure
[4-9]. NHPs that survive past this time point develop
neurological symptoms, with some succumbing to
disease and others surviving. Histopathologic compari-
son of tissue from NHPs or humans that succumb to
MACV infection revealed hemorrhaging and necrosis in
various organs (with some differences between human
and NHP findings), but none of these manifestations
were thought to be severe enough to cause death [6,10].
Early studies showed that MACV was also lethal in
adult guinea pigs, suckling mice and hamsters [5]. How-
ever, there are only minimal reports describing MACV
pathogenesis in animals. In NHP models, while limited
viremia data are available, only minimal work has been
done to describe MACV pathogenesis, and virtually no
studies have analyzed immune responses to infection.
Guinea pigs can be lethally infected with MACV, but
features of the disease course in these animals are
almost completely uncharacterized, as data on viral
replication, pathology, and host response are lacking [5].
MACV is not lethal in adult immunocompetent mice
[5], making characterization of the disease and evalua-
tion of candidate therapeutic compounds difficult.
Recently, mice lacking interferon responses have been
used as models for infection with other hemorrhagic
fever viruses, including Ebola, Marburg, Junín, and
Crimean-Congo Hemorrhagic Fever viruses [11-14].
* Correspondence: sina.bavari@us.army.mil
United States Army Medical Research Institute of Infectious Diseases, Fort
Detrick, Maryland, USA
Bradfute et al. Virology Journal 2011, 8:300
http://www.virologyj.com/content/8/1/300
© 2011 Bradfute et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Signal transducer and activator of transcription 1
(STAT-1) knockout mice are defective in type I, II, and
III interferon signaling. The objective of this study was
to test STAT-1 knockout mice as an adult mouse model
for MACV pathogenesis and immunity.
Methods
Mice and infection
Male and female STAT-1 knockout mice, 6-12 weeks
old, were obtained from Taconic Farms. Infections were
performed with approximately 1000 PFU of wild-type
Machupo virus (strain Carvallo) which had been pas-
saged 3-4 times in suckling hamster brain and subse-
quently twice in Vero cell culture. For lethality studies,
mice were scored at least twice daily for health and
appearance, and any moribund mice were euthanized.
For serial sampling studies, four mice were euthanized
before (day 0) and on days 3, 5, and 7 after virus chal-
lenge. This was done twice, and the data were pooled.
Research performed at The United States Army Medical
Research Institute of Infectious Diseases (USAMRIID)
was conducted under an IACUC approved animal pro-
tocol in compliance with the Animal Welfare Act and
other federal statutes and regulations relating to animals
and experiments involving animals and adheres to prin-
ciples stated in the G u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals (National Research Council, 1996).
USAMRIID is fully accredited by the Association for the
Assessment and Accreditation of Laboratory Animal
Care International. All virus work was performed and
all infected mice were handled under maximum con-
tainment in a biosafety level-4 laboratory at USAMRIID.
Hematology and Chemistry analysis
Blood samples from anesthetized mice were collected, by
cardiac puncture, in EDTA tubes. For hematology analy-
sis, blood was analyzed with a Beckman Coulter ACT 10
counter. Whole blood was further processed by centrifu-
gation at 10,000 RPM for 1 minute for plasma isolation,
which was then tested using comprehensive metabolic
panels and an Abaxis Piccolo chemistry analyzer.
Histopathologic sampling
Four animals were randomly chosen for gross necropsy
on days 0, 3, 5, and 7. Tissues were collected in 10%
neutral buffered formalin and held in the biosafety-
level-4 laboratory for > 21 days. Tissues were then
embedded in paraffin, thin sectioned for histology, and
stained with hematoxylin and eosin for routine light
microscopy.
Ribavirin studies
Groups of 5 STAT-1 knockout mice were administered
100 mg/kg ribavirin (in water) intraperitoneally 1 hour
after infection with 1000 pfu MACV. A control group
received water. Each group received daily injections
through day 12 and was monitored for survival. This
study was performed twice and data were pooled.
Statistical analysis
Two-tailed T-tests were performed to compare test
groups to day 0 samples, and statistical significance is
denoted where p ≤ 0.05.
Cytokine analysis
Plasma cytokine levels were measured using a Cytokine
Bead Array Flex Set kit (BD Biosciences) according to
the manufacturer’s protocol. Samples were analyzed on
a BD FACSCanto II.
Results
The disease progression and lethality of MACV infec-
tion was assessed in STAT-1 knockout mice. Infection
of STAT-1 knockout mice with ~1,000 pfu of MACV
via the intraperitoneal route resulted in lethality (defined
by either death, or euthanasia of moribund mice) in 6/6
mice (mean time to death (MTD) 7.3 ± 0.5) (Figure 1A).
Mice began to appear ruffled, hunched, and lethargic
approximately five days after infection. Subcutaneous
infection of STAT-1 knockout mice resulted in death in
4 of 6 mice, with a delayed time-to-death (MTD 10.5 ±
1.3), while intranasal infection was lethal in only 1 of 4
mice (death on day 20). Therefore, intraperitoneal infec-
tion appeared to be the most uniformly lethal route of
administration, and was performed in subsequent sam-
pling and drug evaluation studies.
Serial sampling studies (days 0, 3, 5, and 7 post-infec-
tion) were performed to investigate the pathogenesis of
MACV lethal infection in STAT-1 knockout mice. Viral
titers were detected in spleen and kidney on day 3 at
low levels (≈100 pfu/g tissue) (Figure 1B). By days 5 and
7, virus had spread to other organs, and higher viral
titers of between 10
5 and 10
7 pfu/g tissue (or pfu/mL
plasma) were detected in all tissues analyzed (plasma,
spleen, lung, liver, and kidney).
Plasma was analyzed for evidence of metabolic altera-
tions during infection. Concentrations of both alanine
aminotransferase (ALT) (which is often indicative of
damage to hepatocytes) and aspartate aminotransferase
(AST) (which is indicative of damage to cells of major
organs such as the liver, heart, skeletal muscle, kidney,
and brain) rose dramatically on day 7 (Figure 2A). Addi-
tionally, total protein concentration increased, which
can be associated with inflammation. Albumin concen-
tration dropped significantly, which can be indicative of
inflammation and shock. Blood urea nitrogen also rose
on day 7 after falling on day 5. Chloride concentration
dropped slightly on day 7, while glucose dropped on
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pattern of changes for these three parameters points to
possible liver and kidney damage and malfunction,
although further research should be conducted to con-
firm this hypothesis. No significant changes were
observed in total bilirubin concentration.
Hematological analysis revealed a substantial increase
in white blood cell counts during the course of infection
(Figure 2B). Platelet levels decreased somewhat on day 5
post-infection (p = 0.073) before rebounding on day 7.
Interestingly, hemoglobin and hematocrit levels slightly
decreased as infection progressed, as did mean corpus-
cular hemoglobin (MCH) and mean corpuscular hemo-
globin concentration (MCHC) levels (Figure 2B).
Cytokine and chemokine levels were analyzed in
plasma from MACV-infected STAT-1 knockout mice
(Figure 3). The levels of IFN-gamma, IL-5, KC (mouse
Figure 1 Wild-type MACV is lethal in STAT-1 knockout mice.A )
STAT-1 knockout mice were infected with 1000 pfu MACV via the
intraperitoneal (n = 6), subcutaneous (n = 6), or intranasal route (n
= 4) and monitored for survival. Intraperitoneal infection was used
for subsequent studies. B) Tissue samples were harvested at days 3,
5, and 7 after MACV infection and evaluated for viral load (plasma, n
= 7-8; spleen, liver, lung, kidney n = 4).
Figure 2 Hematology and plasma chemistry analysis. A) Plasma
was harvested on days 0, 3, 5, and 7 after MACV infection and
analyzed for changes in plasma chemistry parameters. B) Whole
blood was analyzed for white blood cell and platelet counts, as well
as hemoglobin and hematocrit levels. *p < 0.05.
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beta, TNF-alpha, G-CSF, and RANTES were all elevated
on days 5 and/or 7, relative to day 0. However, no
changes were detected in IL-3, IL-4, IL-9, IL-21, GM-
CSF, IL-17A, or IL-1 beta (data not shown).
Tissues were taken from MACV-infected STAT-1
knockout mice and analyzed for histopathological
changes (Figure 4). Mild to moderate hepatocellular
degeneration and necrosis were found in day 7 animals,
consistent with liver injury (Figure 2A). Lymphocyte
death was present in thymus, spleen, and lymph nodes
as early as day 3, and increased as infection progressed
through day 7. Mice presented extensive thymic cortical
atrophy, and moderate to marked splenic lymphocyte
Figure 3 Cytokine and chemokine analysis. Concentrations of 17 different cytokines and chemokines in plasma was evaluated on days 0, 3, 5,
and 7 post-infection (n = 6-7). *p < 0.05.
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was variably extensive peritonitis and necrotizing steati-
tis found in day 5 and day 7 animals. The lesions were
most prominent in and around pancreatic lobes but the
inflammation did not appear to involve the pancreas in
day 5 animals; however all animals from day 7 termina-
tion had mild to marked pancreatitis.
We also investigated the suitability of the MACV STAT-
1 knockout model for testing antiviral therapeutics.
Ribavirin has been previously used to treat two human
patients infected with MACV [15]; although both survived,
it has not been conclusively shown that ribavirin was
responsible for protection. A recent study demonstrated
partial efficacy of ribavirin in guinea pigs infected with
MACV [16]. To test the efficacy of ribavirin, and to
demonstrate the utility of this model for drug discovery
studies, STAT-1 knockout mice were infected with
MACV, and ribavirin (100 mg/kg/day) or water was admi-
nistered i.p. beginning one hour post-infection and conti-
nuing daily for 12 days. As shown in Figure 5, ribavirin
treatment protected 60% of mice from death, and the mice
that succumbed to infection had a significantly later mean
time-to-death than untreated mice (11.5 ± 1.0 days for
ribavirin treated vs. 7.8 ± 0.1 days for water treated mice;
p < 0.01). These antiviral efficacy data support the use of
STAT-1 knockout mice as a platform to test antiviral ther-
apeutics for efficacy against MACV infection.
Discussion
In this study, STAT-1 knockout mice were infected with
MACV, resulting in a lethal small animal model for this
arenavirus. To date, lethal models of MACV infection
which seem to somewhat accurately model human
infections have been limited to NHPs [5,6,9,17,18]. This
underscores a need for a small animal model to enable
collection of data for a better understanding of MACV
immunopathogenesis, and as a tool for antiviral thera-
peutics discovery. Because arenaviruses can block host
IFN responses to establish infection, mice lacking ele-
ments of the interferon response pathway were attrac-
tive candidates for development of small animal models.
It has recently been demonstrated that the Z protein of
New World arenaviruses (including MACV) binds to
the retinoic acid-inducible gene I (RIG-I) protein and
subsequently inhibits IFN-beta responses [19]. Addition-
ally, MACV nucleoprotein blocks nuclear translocation
of interferon regulatory factor 3 (IRF-3) and inhibits
activation of promoters dependent on IRF-3 and IFN-
beta [20]. Therefore, our data are in agreement with
these studies to show that type I IFN responses may be
crucial for control of MACV infection.
The intraperitoneal route of infection of STAT-1
knockout mice with MACV resulted in a much more
rapid and lethal disease course compared to subcuta-
neous or intranasal routes (Figure 1A). Published NHP
studies for MACV infection have been conducted with
subcutaneous infection, which results in death ranging
from ~8-30 days [5-7,21]. Interestingly, subcutaneous
infection of NHPs does not consistently result in uni-
form lethality, which is in agreement with what is
reported here. Future studies could investigate whether
an alternate route of infection of NHPs would alter
Figure 4 Pathology. Panels on the left of the figure (A, C, E and G)
show representative photomicrographs of H&E stained sections of
spleen, pancreas, thymus, and liver, respectively, removed from
uninfected mice at day 0. Panel B shows the representative
disruption of the splenic white pulp architecture at day 7 post-
infection, with marked lymphocyte death (example in enlarged
inset). Panel D demonstrates pancreatitis, which was observed in all
4 animals at day 7 post infection. Panel F is an example of the
complete thymic cortical atrophy observed in all day 7 post-
infection mice. Panel H is a representative sample of day 7 liver,
demonstrating mild to moderate areas of inflammation and necrosis
(left arrow) and regions of hepatocellular degeneration and cell
death (right arrow) (Panels A, B, G and H at 200x magnification,
scale bar is 50 microns; Panels C, D, E and F, scale bar is 10
microns).
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death.
Virus was detected in the plasma and organs of
MACV infected STAT-1 mice. The virus appeared to
have an early tropism for the spleen and kidney (day 3)
in this rodent model (Figure 1B). MACV spread by day
5 to all other organs sampled, and titers remained high
until the time of death (day 7). To our knowledge, this
is the first study to analyze MACV viral titers in tissues
at different points after infection.
Very little data have been published for clinical chem-
istry values in plasma of MACV-infected animals or
patients. One study reported various parameters at dif-
ferent time points for only 3 patients, although baseline
values for these individuals were not available [15]. This
study suggested elevated AST and ALT values after pre-
sentation of symptoms; BUN and creatinine levels were
moderately elevated or normal. While hamsters, marmo-
sets, African green monkeys and rhesus monkeys have
all been described to be susceptible to MACV infection,
very few clinical chemistry values were reported and
therefore comparative analysis is challenging. There was
one report of normal bilirubin levels in rhesus monkeys,
which the authors believed to reflect little to no intra-
vascular hemorrhage in this model at that time point
[9]. The data reported here comprise the first study to
present a dataset from an animal model for several
important clinical chemistry parameters. There is evi-
dence of liver and possible kidney damage in MACV
infected STAT-1 mice, as revealed by significantly ele-
vated AST, ALT, BUN, and decreased chloride, glucose,
and albumin levels (Figure 2A). Total bilirubin did not
change in these animals, similar to what was noted in
rhesus monkeys [9]. A more thorough assessment of
values for clinical chemistry parameters across various
species of animal models, as well as human infections, is
needed.
Total white blood cell counts increased over the
course of MACV infection of STAT-1 knockout mice
(Figure 2B). In NHP or human MACV infections, how-
ever, white blood cell count (or lymphocyte and neutro-
phil counts) decline before recovering [9,17].
Additionally, thrombocytopenia is a hallmark of human
and NHP MACV infection [2,9,22], but only mild
decreases in platelet counts were found in STAT-1
knockout mice (p = 0.073 on day 5; Figure 2B). Follow-
ing MACV infection, hematocrit levels declined in
STAT-1 knockout mice (Figure 2B). Importantly,
decreased hematocrit levels have been reported in rhe-
sus and African green monkeys [9,17]. STAT-1 knock-
out mice also had decreased MCH, MCHC, and
hemoglobin levels during infection, which can be indica-
tive of the observed decreased hematocrit levels.
Virtually no work has been reported on cytokine pro-
duction in response to MACV infection. The data
reported herein suggest a dysregulated cytokine/chemo-
kine response towards the end of lethal MACV infec-
tion, with elevated pro- and anti-inflammatory
mediators (Figure 3). It is noteworthy that elevated
levels of IL-6, IL-8, IL-10, G-CSF, and TNF-alpha,
which were observed in MACV-infected STAT-1 knock-
out mice (Figure 3), are correlated with the severity of
human Argentinean hemorrhagic fever, caused by the
related Junín virus [23-25]. It has been hypothesized
that one mechanism of hemorrhagic fever virus patho-
genesis is late stage elaboration of uncontrolled pro-
inflammatory cytokine responses and release of vasoac-
tive mediators. These mediators may contribute to
decreases in endothelial cell function leading to vascular
leakiness, although this mechanism has yet to be pre-
cisely described for arenaviruses [26]. Although it is
probable that cytokine levels in STAT-1 knockout mice
will be altered due to their inability to respond to type I,
II, and III IFNs, the cytokine data reported here can
serve as a reference for future MACV studies in other
immunocompetent animal models.
We completed a histopathological examination of all
thoracic and abdominal organs, as well as brain and
cephalic tissues. The most significant histopathological
findings were mild to moderate liver damage, moderate
to marked lymphocyte death in lymph nodes, spleen
and thymus, and pancreatitis (Figure 4). These findings
have also been reported to varying degrees in other
MACV models. Lymphoid depletion in the splenic white
pulp was described for MACV-infected rhesus monkeys
[6], while infected marmosets demonstrated cortical
necrosis of lymph nodes and splenic reticular hyperpla-
sia with lymphoid depletion [5]. MACV-infected African
green monkeys showed moderate hepatocellular necrosis
with fatty changes, mild to moderate pancreatitis, and
mild to moderate lymphoid cell depletion with necrosis
in the spleen, lymph nodes and thymus [7]. There have
not been additional comparable histopathological ana-
lyses performed in MACV NHP models in decades.
NHPs tend to have a biphasic disease course after
MACV infection, with most deaths occurring in the first
“acute” phase. Surviving NHPs tend to undergo a sec-
ond, prolonged disease state, characterized by neurologi-
cal disease [21]. This second phase has not been
described in human MACV infection (to our knowl-
edge) or in the STAT-1 knockout model. However, due
to a lack of data, it is not feasible to conclusively com-
pare the faithfulness of different MACV infection mod-
els to each other or the human disease course. Overall,
there are important similarities and differences in the
disease course of these models, and further work must
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out mice to NHP models or human infections.
The STAT-1 knockout mouse model was evaluated by
testing the efficacy of ribavirin against MACV disease.
The antiviral drug ribavirin has been shown to be pro-
tective in MACV-infected guinea pigs [16], and has
been used to treat two human MACV-infected patients
[15]. The results reported here indicate that ribavirin
protected STAT-1 knockout mice against MACV dis-
ease, verifying the efficacy of ribavirin and supporting
the utility of the STAT-1 knockout model for drug effi-
cacy studies (Figure 5).
Mice lacking type I and II IFN signaling (IFNalpha/
beta receptor KO/IFN-gamma receptor KO mice) have
been shown to be susceptible to Junín virus infection,
leading to weight loss of >15-20%, at which point mice
were euthanized [13]. Splenic necrosis and lymphocyte
depletion were not apparent in these mice, but kidney
and liver inflammation and necrosis were prominent.
MACV-infected STAT1 KO mice also had liver necrosis,
but in contrast to the Junín virus model, splenic lym-
phocyte death was prevalent. Further work is necessary
to compare how similar these mouse models are to each
other and to their respective human disease courses.
Conclusions
T h e s ed a t as u g g e s tt h eS T A T - 1k n o c k o u tm o u s ei sa
useful small animal model for investigation of efficacy of
antiviral therapeutics as well as preliminary studies of
immune responses to MACV infection. MACV infec-
tions in mouse, guinea pig and NHP species should be
characterized in more detail to provide well-understood
models for investigation of therapeutics and vaccines.
Further characterization of these models is required to
advance the development of countermeasures for arena-
viral hemorrhagic fevers.
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